Fabomotizol

Fabomotizol
IUPAC ime
	5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole
Klinički podaci
Način primene	Oralno
Pravni status
Pravni status	℞ (Prescription only);
Identifikatori
CAS broj	173352-39-1
ATC kod	none
PubChem	CID 9862937
ChemSpider	8038633
Hemijski podaci
Formula	C15H21N3O2S
Molarna masa	307,410 g/mol
	SMILES C3COCCN3CCSc(nc1c2)nc1ccc2OCC; ;
	InChI InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17) ; Key:WWNUCVSRRUDYPP-UHFFFAOYSA-N ;

Afobazol je lek sa anksiolitičkim i neurozaštitnim dejstvom. On ne deluje kao sedativ ili relaksant mišića, te je stoga njegovo dejstvo selektivnije od mnogih drugih lekova sa sličnom primenom. Ovaj lek se pojavio na ruskom tržištu ranih 2000-ih.

Mehanizam dejstva afobazola je delimično poznat. Smatra se da promoviše oslobađanje GABA, NGF i BDNF, da je antagonist MT1 i MT3 receptor, kao i agonist sigma receptora.^[1]^[2]^[3]^[4]^[5]

Klinička ispitivanja su pokazala da je afobazol dobro tolerisan i da je efikasan u lečenju anksioznosti. Šira klinička ispitivanja izvan Rusije još nisu izvršena.^[6]

Reference

^ Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). „Clinical study of the selective anxiolytic agent afobazol”. Eksperimental'naia i klinicheskaia farmakologiia. 64 (2): 15—9. PMID 11548440.
^ Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). „Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon”. Eksperimental'naia i klinicheskaia farmakologiia. 68 (1): 20—4. PMID 15786959.
^ Seredin, SB; Melkumian, DS; Val'dman, EA; Iarkova, MA; Seredina, TC; Voronin, MV; Lapitskaia, AS (2006). „Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction”. Eksperimental'naia i klinicheskaia farmakologiia. 69 (3): 3—6. PMID 16878488.
^ Antipova, TA; Sapozhnikova, DS; Bakhtina, LIu; Seredenin, SB (2009). „Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons”. Eksperimental'naia i klinicheskaia farmakologiia. 72 (1): 12—4. PMID 19334503.
^ Seredenin, SB; Antipova, TA; Voronin, MV; Kurchashova, SY; Kuimov, AN (2009). „Interaction of afobazole with sigma1-receptors”. Bulletin of experimental biology and medicine. 148 (1): 42—4. PMID 19902093.
^ Medvedev, VE; Trosnova, AP; Dobrovol'skiĭ, AV (2007). „Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov. 107 (7): 25—9. PMID 18379478.

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). „Clinical study of the selective anxiolytic agent afobazol”. Eksperimental'naia i klinicheskaia farmakologiia. 64 (2): 15—9. PMID 11548440.

[2] Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). „Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon”. Eksperimental'naia i klinicheskaia farmakologiia. 68 (1): 20—4. PMID 15786959.

[3] Seredin, SB; Melkumian, DS; Val'dman, EA; Iarkova, MA; Seredina, TC; Voronin, MV; Lapitskaia, AS (2006). „Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction”. Eksperimental'naia i klinicheskaia farmakologiia. 69 (3): 3—6. PMID 16878488.

[4] Antipova, TA; Sapozhnikova, DS; Bakhtina, LIu; Seredenin, SB (2009). „Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons”. Eksperimental'naia i klinicheskaia farmakologiia. 72 (1): 12—4. PMID 19334503.

[5] Seredenin, SB; Antipova, TA; Voronin, MV; Kurchashova, SY; Kuimov, AN (2009). „Interaction of afobazole with sigma1-receptors”. Bulletin of experimental biology and medicine. 148 (1): 42—4. PMID 19902093.

[6] Medvedev, VE; Trosnova, AP; Dobrovol'skiĭ, AV (2007). „Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov. 107 (7): 25—9. PMID 18379478.

[1]

[2]

[3]

[4]

[5]

[6]